Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis.
Yan JiangYanan HuoYufeng LiXijian KongBingwu WangFeng LiuXin ZhengYukun LiYunfa YangYongsheng XuQingyun XueZhitian HuYanfeng XiaoWen MaYinhan GuoWei YuWeibo XiaPublished in: Expert opinion on biological therapy (2024)
NCT05215977 (ClinicalTrials.gov.).